1. Cgp 39393
2. Cgp-39393
3. Desulfatohirudin
4. Desulphatohirudin
5. Ik-hir02
6. Iprivask
7. Recombinant Hv1 Hirudin
8. Revasc
1. Cgp 39393
2. Cgp-39393
3. 120993-53-5
4. Desirudin [usan:inn:ban]
5. Unii-u0jz726775
6. Gtpl6458
7. Hirudin (hirudo Medicinalis Isoform Hv1), 63-desulfo-
8. Dtxsid90153094
9. Cgp39393
10. U0jz726775
Molecular Weight | 6963 g/mol |
---|---|
Molecular Formula | C287H440N80O110S6 |
XLogP3 | -40.1 |
Hydrogen Bond Donor Count | 99 |
Hydrogen Bond Acceptor Count | 121 |
Rotatable Bond Count | 165 |
Exact Mass | 6961.9720340 g/mol |
Monoisotopic Mass | 6958.9619695 g/mol |
Topological Polar Surface Area | 3240 Ų |
Heavy Atom Count | 483 |
Formal Charge | 0 |
Complexity | 18600 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 62 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
1 of 2 | |
---|---|
Drug Name | Iprivask |
PubMed Health | Desirudin (Injection) |
Drug Classes | Anticoagulant |
Active Ingredient | Desirudin recombinant |
Dosage Form | Injectable |
Route | Subcutaneous |
Strength | 15mg/vial |
Market Status | Prescription |
Company | Marathon Pharms |
2 of 2 | |
---|---|
Drug Name | Iprivask |
PubMed Health | Desirudin (Injection) |
Drug Classes | Anticoagulant |
Active Ingredient | Desirudin recombinant |
Dosage Form | Injectable |
Route | Subcutaneous |
Strength | 15mg/vial |
Market Status | Prescription |
Company | Marathon Pharms |
Indicated as prophylaxis of deep vein thrombosis for patients undergoing hip replacement surgery.
Prevention of deep venous thrombosis in patients undergoing elective hip or knee replacement surgery.
Desirudin results in dose-dependent prolongation of the activated partial thromboplastin time (aPTT).
Anticoagulants
Agents that prevent BLOOD CLOTTING. (See all compounds classified as Anticoagulants.)
Fibrinolytic Agents
Fibrinolysin or agents that convert plasminogen to FIBRINOLYSIN. (See all compounds classified as Fibrinolytic Agents.)
B01AE01
B - Blood and blood forming organs
B01 - Antithrombotic agents
B01A - Antithrombotic agents
B01AE - Direct thrombin inhibitors
B01AE01 - Desirudin
Absorption
Absorption is complete after subcutaneous administration. Time to peak in plasma is 1 to 3 hours.
Route of Elimination
Urine (40% to 50% as unchanged drug).
Volume of Distribution
0.25 L/kg.
Clearance
1.5 to 2.7 mL/min/kg.
Human and animal data suggest that desirudin is primarily eliminated and metabolized by the kidney. The total urinary excretion of unchanged desirudin amounts to 40 to 50% of the administered dose. Metabolites lacking one or two C-terminal amino acids constitute a minor proportion of the material recovered from urine (< 7%). There is no evidence for the presence of other metabolites. This indicates that desirudin is metabolized by stepwise degradation from the C-terminus probably catalyzed by carboxypeptidase(s) such as carboxypeptidase A.
~2 hours.
Desirudin is a direct, highly selective thrombin inhibitor. Reversibly binds to the active thrombin site of free and clot-associated thrombin. Inhibits fibrin formation, activation of coagulation factors V, VII, and XIII, and thrombin-induced platelet aggregation resulting in a dose-dependent prolongation of the activated partial thromboplastin time (aPTT).